Which stock is cheaper: MANKIND or CIPLA?

Based on Price to Earnings, MANKIND trades at a P/E of 50.6 while CIPLA trades at a P/E of 32.3.

Does MANKIND or CIPLA have higher ROCE?

MANKIND generates an ROCE of 15.6% compared to CIPLA's ROCE of 15.9%.

MANKIND PHARMA LIMITED (MANKIND) has a market cap of ₹94,174 Cr compared to CIPLA LTD (CIPLA) with ₹1,10,353 Cr.

MANKINDHealthcare

₹2,492.80+0.95%

Market Cap: ₹94,174 Cr

CIPLAHealthcare

Leads (3/5)

₹1,378.90+1.54%

Market Cap: ₹1,10,353 Cr

Automated quantitative breakdown of fundamental strengths between MANKIND and CIPLA.

Attractive ValuationCIPLA (P/E 32.3)Trades at lower Price-to-Earnings

Capital EfficiencyCIPLA (ROCE 15.9%)Superior operating return on capital

Balance Sheet SafetyCIPLALower debt-to-equity ratio

Shareholder YieldMANKIND (8.00%)Higher annual dividend yield

Green highlight indicates the stronger metric

Financial Metric	MANKIND	CIPLA
Valuation Multiples
Market Capitalization	₹94,174 Cr	₹1,10,353 Cr
Price to Earnings (P/E)	50.58	32.32
Price to Book (P/B)	5.74	3.23
Profitability & Capital Efficiency
Return on Capital Employed (ROCE)	15.58%	15.89%
Return on Equity (ROE)	13.97%	11.12%
Operating Profit Margin (OPM)	21.31%	16.22%
Net Profit Margin (NPM)	17.59%	23.17%
Balance Sheet & Solvency
Debt to Equity Ratio	0.34	0.00
Dividend Yield	8.00%	6.82%
Historical Growth
3-Year Sales Growth (CAGR)	14.17%	1.84%
Latest Quarter Financial Results
Quarterly Revenue (30 Jun 2026)	₹4,031 Cr	₹7,077 Cr
Quarterly Net Profit	₹568 Cr	₹789 Cr